2 Beaten-Down Dividend Growth Stocks to Buy on the Dip
The Motley Fool·2025-07-22 17:57- Novo Nordisk Shares of Novo Nordisk peaked last year as enthusiasm for anti-obesity medications reached a fever pitch. Then compounding pharmacies such as Hims & Hers Health that were allowed to sell their own versions of semaglutide pressured sales somewhat, and this hammered the stock price. Shares of this pharmaceutical giant previously famous for diabetes treatments are down 56% from their peak. A stock market that keeps reaching all-time highs hardly seems like anything for investors to complain abo ...